)
Beijing Scitop Bio-tech Co (300858) investor relations material
Beijing Scitop Bio-tech Co Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was RMB97.14m, down 6.63% YoY; net income attributable to shareholders was RMB10.66m, down 69.57%.
9M revenue was RMB266.65m, down 0.28% YoY; net income was RMB35.75m, down 53.10%.
Financial highlights
9M adjusted net income, excluding non-recurring gains and losses, was RMB25.25m, down 62.36% YoY; Q3 adjusted net income was RMB6.57m, down 79.44%.
9M operating profit was RMB38.55m versus RMB88.51m in 9M 2025; income tax expense fell to RMB2.73m from RMB12.26m.
9M operating cash flow was RMB31.61m, down 56.46% YoY; investing cash flow was RMB141.90m versus an outflow of RMB40.08m in 9M 2025.
Key financial ratios and metrics
Q3 basic and diluted EPS were RMB0.04, each down 69.23% YoY; 9M basic and diluted EPS were RMB0.14, each down 51.72%.
Weighted average ROE was 0.60% for Q3, down 1.34 percentage points YoY, and 1.95% for 9M, down 2.25 points.
Total assets were RMB1,973.63m at Sep. 30, down 2.24% from year-end 2025; shareholder equity was RMB1,761.79m, down 4.40%.
- Net profit dropped 39% despite revenue growth, as new capacity costs outpaced sales gains.300858
Q2 2026 - Revenue up 20.85%, net profit stable, probiotics and microecological agents drive growth.300858
Q4 2025 - Revenue grew but net profit declined; share repurchase plan up to ¥150 million announced.300858
Q1 2026 - Q3 2025 saw strong revenue and profit growth, with major R&D and capacity investments.300858
Q3 2025 - Revenue up 18.32% YoY, net profit down 5.31% amid capacity investment and strong microecological growth.300858
Q2 2025 - Probiotic revenue surged 20.85% year-over-year, driving record net profit and cash flow.300858
Q4 2024 - Net profit rose 7.89% year-over-year, driven by strong probiotics and microecological growth.300858
Q2 2024 - Q3 2024 saw higher revenue but lower net profit, with improved cash flow and rising expenses.300858
Q3 2024 - Q1 2025 saw robust revenue and profit growth, but operating cash flow turned negative.300858
Q1 2025
Next Beijing Scitop Bio-tech Co earnings date
Next Beijing Scitop Bio-tech Co earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)